Indo-Bangla Pharmaceuticals Limited announcements
129 Dhaka Stock Exchange announcements for Indo-Bangla Pharmaceuticals Limited (IBP) since 2018: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2025 (17).
- Resumption after Record Date
Trading of the shares of the company will resume on 08.12.2025.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 07.12.2025.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 03.12.2025 to 04.12.2025 and trading of the shares will remain suspended on record date i.e., 07.12.2025.
- Dividend Declaration
The Board of Directors has recommended 0.15% Cash Dividend for the year ended June 30, 2025. Date of AGM: 30.12.2025, Time: 11:00 AM, Venue: Barishal Club Limited, Club Road, Barishal. Record Date: 07.12.2025. The Company has also reported EPS of Tk. (0.32), NAV per share of Tk. 12.53, and NOCFPS of Tk. 0.50 for the year ended June 30, 2025, as against EPS of Tk. (0.35), NAV per share of Tk. 13.60, and NOCFPS of Tk. 0.29 for the year ended June 30, 2024.
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (16.11.2025) following its corporate declaration.
- Reschedule of Board Meeting under LR 19(1)
The Company has further informed that due to unavoidable circumstances the meeting of the Board of Directors of the Company as per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, will be held on November 15, 2025 at 4:00 PM instead of earlier declared November 12, 2025 at 4:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2025.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 12, 2025 at 4:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2025.
- MoU with Salar Yousafzai Pharma Ltd. for export of pharmaceutical products
The company has informed that the Board of Directors of the company, in its meeting held on 08th July, 2025, has approved the signing of a Memorandum of Understanding (MoU) with Salar Yousafzai Pharma Ltd., a company based in Afghanistan, for the export of pharmaceutical products (medicine) to the Afghan market. Key Points of MoU: Exclusive Export Rights: Salar Yousafzai Pharma Ltd., will act as the sole agent in Afghanistan. Tenure: The MoU is valid for 15 years from 2025 to 2040, (cont.) (Cont. news of IBP): and renewable upon mutual agreement. Minimum Order Value: USD 1.5 Lac per shipment, with regular exports plan. Payment terms: 40% advance TT, 60% pre-shipment. Export on Free on Board (FOB) Chittagong basis. This strategic collaboration is expected to strengthen the Company's financial position through boost export revenue, strengthen foreign currency earnings, and support long-term business growth, thereby enhancing shareholder value. (end)
- Query Response
In response to the DSE query dated July 07, 2025, the company has informed that there is no undisclosed price sensitive information of the company for recent unusual price hike and increase in volume of shares.
- Q3 Financials
(Q3 Un-audited): EPS was Tk. (0.09) for January-March 2025 as against Tk. (0.08) for January-March 2024; EPS was Tk. (0.17) for July 2024-March 2025 as against Tk. (0.13) for July 2023-March 2024. NOCFPS was Tk. 0.02 for July 2024-March 2025 as against Tk. 0.19 for July 2023-March 2024. NAV per share was Tk. 13.43 as on March 31, 2025 and Tk. 13.60 as on June 30, 2024. (cont.) (Cont. news of IBP): The reasons for significant deviation: Earnings per Share (EPS) has been decreased compared to the same period of the previous year due to decreased in sales revenue. NOCFPS has been decreased due to decrease in supplier's payment during the reporting period. NAVPS has also been decreased due to net loss alter tax. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 30, 2025 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.
- Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2024 to the respective shareholders.
- Category Change
The Company will be placed in 'B' category from existing 'Z' category with effect from March 04, 2025 as the Company has reported disbursement of 0.10% Cash Dividend for the year ended June 30, 2024.
- Prohibition on providing loan facilities to purchase securities
The Stock Brokers and Merchant Bankers are requested to abstain from providing loan facilities to purchase the securities of Indo-Bangla Pharmaceuticals Limited in between 1st to 7th trading days following the change of categorization, with effect from March 04, 2025 as per BSEC Directive No. BSEC/CMRRCD/2009-193/32 dated December 26, 2021.
- Q2 Financials
(Q2 Un-audited): EPS was Tk. (0.05) for October-December 2024 as against Tk. (0.06) for October-December 2023; EPS was Tk. (0.08) for July-December 2024 as against Tk. (0.05) for July-December 2023. NOCFPS was Tk. 0.03 for July-December 2024 as against Tk. 0.23 for July-December 2023. NAV per share was Tk. 13.53 as on December 31, 2024 and Tk. 13.60 as on June 30, 2024. The reasons for significant deviation: (cont.) (cont. news IBP): NOCFPS has been decreased due to decrease in supplier's payment during the reporting period. NAVPS has also been decreased due to net loss after tax. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2025 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2024.
- Credit Rating Result
Emerging Credit Rating Limited (ECRL) has affirmed Surveillance rating of the Company as "BBB" in the long term and "ST-3" in the short term along with a Stable outlook based on audited financial statements up to June 30, 2024, unaudited financial statements of 1st quarter of FY2025 and other relevant quantitative as well as qualitative information up to the date of rating.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.